Cargando…

Pulse duration settings in subthalamic stimulation for Parkinson's disease

BACKGROUND: Stimulation parameters in deep brain stimulation (DBS) of the subthalamic nucleus for Parkinson's disease (PD) are rarely tested in double‐blind conditions. Evidence‐based recommendations on optimal stimulator settings are needed. Results from the CUSTOM‐DBS study are reported, comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Steigerwald, Frank, Timmermann, Lars, Kühn, Andrea, Schnitzler, Alfons, Reich, Martin M., Kirsch, Anna Dalal, Barbe, Michael Thomas, Visser‐Vandewalle, Veerle, Hübl, Julius, van Riesen, Christoph, Groiss, Stefan Jun, Moldovan, Alexia‐Sabine, Lin, Sherry, Carcieri, Stephen, Manola, Ljubomir, Volkmann, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813170/
https://www.ncbi.nlm.nih.gov/pubmed/29165837
http://dx.doi.org/10.1002/mds.27238
_version_ 1783300139163582464
author Steigerwald, Frank
Timmermann, Lars
Kühn, Andrea
Schnitzler, Alfons
Reich, Martin M.
Kirsch, Anna Dalal
Barbe, Michael Thomas
Visser‐Vandewalle, Veerle
Hübl, Julius
van Riesen, Christoph
Groiss, Stefan Jun
Moldovan, Alexia‐Sabine
Lin, Sherry
Carcieri, Stephen
Manola, Ljubomir
Volkmann, Jens
author_facet Steigerwald, Frank
Timmermann, Lars
Kühn, Andrea
Schnitzler, Alfons
Reich, Martin M.
Kirsch, Anna Dalal
Barbe, Michael Thomas
Visser‐Vandewalle, Veerle
Hübl, Julius
van Riesen, Christoph
Groiss, Stefan Jun
Moldovan, Alexia‐Sabine
Lin, Sherry
Carcieri, Stephen
Manola, Ljubomir
Volkmann, Jens
author_sort Steigerwald, Frank
collection PubMed
description BACKGROUND: Stimulation parameters in deep brain stimulation (DBS) of the subthalamic nucleus for Parkinson's disease (PD) are rarely tested in double‐blind conditions. Evidence‐based recommendations on optimal stimulator settings are needed. Results from the CUSTOM‐DBS study are reported, comparing 2 pulse durations. METHODS: A total of 15 patients were programmed using a pulse width of 30 µs (test) or 60 µs (control). Efficacy and side‐effect thresholds and unified PD rating scale (UPDRS) III were measured in meds‐off (primary outcome). The therapeutic window was the difference between patients’ efficacy and side effect thresholds. RESULTS: The therapeutic window was significantly larger at 30 µs than 60 µs (P = ·0009) and the efficacy (UPDRS III score) was noninferior (P = .00008). INTERPRETATION: Subthalamic neurostimulation at 30 µs versus 60 µs pulse width is equally effective on PD motor signs, is more energy efficient, and has less likelihood of stimulation‐related side effects. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
format Online
Article
Text
id pubmed-5813170
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58131702018-02-21 Pulse duration settings in subthalamic stimulation for Parkinson's disease Steigerwald, Frank Timmermann, Lars Kühn, Andrea Schnitzler, Alfons Reich, Martin M. Kirsch, Anna Dalal Barbe, Michael Thomas Visser‐Vandewalle, Veerle Hübl, Julius van Riesen, Christoph Groiss, Stefan Jun Moldovan, Alexia‐Sabine Lin, Sherry Carcieri, Stephen Manola, Ljubomir Volkmann, Jens Mov Disord Brief Reports BACKGROUND: Stimulation parameters in deep brain stimulation (DBS) of the subthalamic nucleus for Parkinson's disease (PD) are rarely tested in double‐blind conditions. Evidence‐based recommendations on optimal stimulator settings are needed. Results from the CUSTOM‐DBS study are reported, comparing 2 pulse durations. METHODS: A total of 15 patients were programmed using a pulse width of 30 µs (test) or 60 µs (control). Efficacy and side‐effect thresholds and unified PD rating scale (UPDRS) III were measured in meds‐off (primary outcome). The therapeutic window was the difference between patients’ efficacy and side effect thresholds. RESULTS: The therapeutic window was significantly larger at 30 µs than 60 µs (P = ·0009) and the efficacy (UPDRS III score) was noninferior (P = .00008). INTERPRETATION: Subthalamic neurostimulation at 30 µs versus 60 µs pulse width is equally effective on PD motor signs, is more energy efficient, and has less likelihood of stimulation‐related side effects. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. John Wiley and Sons Inc. 2017-11-22 2018-01 /pmc/articles/PMC5813170/ /pubmed/29165837 http://dx.doi.org/10.1002/mds.27238 Text en © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Reports
Steigerwald, Frank
Timmermann, Lars
Kühn, Andrea
Schnitzler, Alfons
Reich, Martin M.
Kirsch, Anna Dalal
Barbe, Michael Thomas
Visser‐Vandewalle, Veerle
Hübl, Julius
van Riesen, Christoph
Groiss, Stefan Jun
Moldovan, Alexia‐Sabine
Lin, Sherry
Carcieri, Stephen
Manola, Ljubomir
Volkmann, Jens
Pulse duration settings in subthalamic stimulation for Parkinson's disease
title Pulse duration settings in subthalamic stimulation for Parkinson's disease
title_full Pulse duration settings in subthalamic stimulation for Parkinson's disease
title_fullStr Pulse duration settings in subthalamic stimulation for Parkinson's disease
title_full_unstemmed Pulse duration settings in subthalamic stimulation for Parkinson's disease
title_short Pulse duration settings in subthalamic stimulation for Parkinson's disease
title_sort pulse duration settings in subthalamic stimulation for parkinson's disease
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813170/
https://www.ncbi.nlm.nih.gov/pubmed/29165837
http://dx.doi.org/10.1002/mds.27238
work_keys_str_mv AT steigerwaldfrank pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT timmermannlars pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT kuhnandrea pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT schnitzleralfons pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT reichmartinm pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT kirschannadalal pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT barbemichaelthomas pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT visservandewalleveerle pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT hubljulius pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT vanriesenchristoph pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT groissstefanjun pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT moldovanalexiasabine pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT linsherry pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT carcieristephen pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT manolaljubomir pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease
AT volkmannjens pulsedurationsettingsinsubthalamicstimulationforparkinsonsdisease